Optimize vaccine immune response


Lonza’s proprietary Epibase® in silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in protein-based vaccine targets.  The tool is driven by sequence information, structural bioinformatics and experimental data.  The Epibase®  in silico tool predicts potential peptide binding to HLA Class I and Class II molecules to drive a subsequent T cell response.  In order to provide the optimal number of antigens that confer the broadest protection against infection, Epibase® in silico can identify conserved regions across several virus strains in order to help design vaccines for maximum coverage.

The Epibase® in silico tool supports lead candidate selection, ranking, optimization and rational design for the development of efficacious vaccines.

Help Increase Chance of Clinical Success

  • 35 HLA Class I and 85 HLA Class II allotypes are represented
  • Analysis includes binding affinity, promiscuity and frequency of allotypes
  • High accuracy of prediction based on in vitro correlations
  • Enhance immune response with in silico-guided engineering of epitope sequences
  • Lonza can link in silico results with Epibase® in vitro assays for confirmation of promising vaccine candidates

Save Time and Money in Development

  • Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
  • Rapidly assess vaccine candidates with a high throughput process
  • Streamline candidate selection using in silico screening to select the most suitable candidates before proceeding to in vitro screening 
  • Focus R&D resources on a smaller number of vaccine candidates with the greatest chance of success early in development